http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Dec 2025 08:01:43 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709801.html <p>Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the WHITE proxy card FOR BOTH of the Company’s director nominees – Peter Miles Davies and David Wilson. As previously disclosed, Lynx1 Capital Management (“Lynx1”) is conducting a proxy contest and is seeking the election at the 2025 Annual Meeting of two director candidates in opposition to the highly http://www.streetinsider.com/Corporate+News/ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709801.html Mon, 08 Dec 2025 08:01:43 -0500 NEUP http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Press+Releases/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html <p align="center"><em>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the </em><strong><em>WHITE</em></strong> <em>Proxy Card </em></p> <p align="justify">BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on the <strong>WHITE</strong> proxy card <strong>FOR BOTH</strong> of the Company’s director nominees – <strong>Peter Miles Davies </strong>and <strong>David Wilson</strong>. As previously disclosed, http://www.streetinsider.com/Globe+Newswire/Leading+Proxy+Advisory+Firm+ISS+Recommends+that+Shareholders+Vote+the+WHITE+Proxy+Card+FOR+Both+of+Neuphoria%E2%80%99s+Director+Nominees/25709732.html Mon, 08 Dec 2025 08:00:00 -0500 A.04719031 A.33378433 NEUP O.00176107 O.01836073 O.67404898 http://www.streetinsider.com/Corporate+News/Neuphoria+rejects+Lynx1%27s+revised+%244.75+acquisition+offer/25698795.html <p>Neuphoria Therapeutics Inc. (NASDAQ: NEUP) rejected a revised acquisition proposal from dissident stockholder Lynx1 Master Fund LP, stating the $4.75 per share offer undervalues the company and provides no meaningful premium to stockholders.</p><p>The clinical-stage biotechnology company said Lynx1's new bid is lower than its initial proposal and priced near estimated cash value. Neuphoria's board characterized the offer as failing to reflect the value of licensing agreements that have generated tens of millions in revenue with potential for additional milestone payments.</p><p>Neuphoria is conducting a strategic alternatives review with financial advisor H.C. Wainwright & Co. The company said it has received substantial http://www.streetinsider.com/Corporate+News/Neuphoria+rejects+Lynx1%27s+revised+%244.75+acquisition+offer/25698795.html Thu, 04 Dec 2025 08:02:57 -0500 NEUP http://www.streetinsider.com/Mergers+and+Acquisitions/Neuphoria+rejects+Lynx1%27s+revised+%244.75+acquisition+offer/25698795.html <p>Neuphoria Therapeutics Inc. (NASDAQ: NEUP) rejected a revised acquisition proposal from dissident stockholder Lynx1 Master Fund LP, stating the $4.75 per share offer undervalues the company and provides no meaningful premium to stockholders.</p><p>The clinical-stage biotechnology company said Lynx1's new bid is lower than its initial proposal and priced near estimated cash value. Neuphoria's board characterized the offer as failing to reflect the value of licensing agreements that have generated tens of millions in revenue with potential for additional milestone payments.</p><p>Neuphoria is conducting a strategic alternatives review with financial advisor H.C. Wainwright & Co. The company said it has received substantial http://www.streetinsider.com/Mergers+and+Acquisitions/Neuphoria+rejects+Lynx1%27s+revised+%244.75+acquisition+offer/25698795.html Thu, 04 Dec 2025 08:02:57 -0500 NEUP http://www.streetinsider.com/Press+Releases/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html <p align="center"><em>Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest</em></p> <p align="center"><em>Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card</em></p> <p>BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP’s (“Lynx1”), revised indication of interest to acquire the Company.</p> <p><strong>Lynx1 Operating Outside Neuphoria’s Robust and Ongoing Strategic http://www.streetinsider.com/Press+Releases/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html Thu, 04 Dec 2025 08:00:00 -0500 A.33378433 NEUP O.01836073 O.67404898 http://www.streetinsider.com/Press+Releases/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html <p align="center"><em>Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest</em></p> <p align="center"><em>Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card</em></p> <p>BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP’s (“Lynx1”), revised indication of interest to acquire the Company.</p> <p><strong>Lynx1 Operating Outside Neuphoria’s Robust and Ongoing Strategic http://www.streetinsider.com/Press+Releases/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html Thu, 04 Dec 2025 08:00:00 -0500 A.33378433 NEUP O.01836073 O.67404898 http://www.streetinsider.com/Press+Releases/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html <p align="center"><em>Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest</em></p> <p align="center"><em>Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card</em></p> <p>BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP’s (“Lynx1”), revised indication of interest to acquire the Company.</p> <p><strong>Lynx1 Operating Outside Neuphoria’s Robust and Ongoing Strategic http://www.streetinsider.com/Press+Releases/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html Thu, 04 Dec 2025 08:00:00 -0500 A.33378433 NEUP O.01836073 O.67404898 http://www.streetinsider.com/Press+Releases/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html <p align="center"><em>Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest</em></p> <p align="center"><em>Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card</em></p> <p>BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP’s (“Lynx1”), revised indication of interest to acquire the Company.</p> <p><strong>Lynx1 Operating Outside Neuphoria’s Robust and Ongoing Strategic http://www.streetinsider.com/Press+Releases/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html Thu, 04 Dec 2025 08:00:00 -0500 A.33378433 NEUP O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html <p align="center"><em>Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest</em></p> <p align="center"><em>Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card</em></p> <p>BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP’s (“Lynx1”), revised indication of interest to acquire the Company.</p> <p><strong>Lynx1 Operating Outside Neuphoria’s Robust and Ongoing Strategic http://www.streetinsider.com/Globe+Newswire/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html Thu, 04 Dec 2025 08:00:00 -0500 A.33378433 NEUP O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html <p align="center"><em>Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest</em></p> <p align="center"><em>Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card</em></p> <p>BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP’s (“Lynx1”), revised indication of interest to acquire the Company.</p> <p><strong>Lynx1 Operating Outside Neuphoria’s Robust and Ongoing Strategic http://www.streetinsider.com/Globe+Newswire/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html Thu, 04 Dec 2025 08:00:00 -0500 A.33378433 NEUP O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html <p align="center"><em>Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest</em></p> <p align="center"><em>Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card</em></p> <p>BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP’s (“Lynx1”), revised indication of interest to acquire the Company.</p> <p><strong>Lynx1 Operating Outside Neuphoria’s Robust and Ongoing Strategic http://www.streetinsider.com/Globe+Newswire/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html Thu, 04 Dec 2025 08:00:00 -0500 A.33378433 NEUP O.01836073 O.67404898 http://www.streetinsider.com/Globe+Newswire/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html <p align="center"><em>Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest</em></p> <p align="center"><em>Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card</em></p> <p>BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to dissident stockholder, Lynx1 Master Fund LP’s (“Lynx1”), revised indication of interest to acquire the Company.</p> <p><strong>Lynx1 Operating Outside Neuphoria’s Robust and Ongoing Strategic http://www.streetinsider.com/Globe+Newswire/Neuphoria+Responds+to+Lynx1%E2%80%99s+Revised+Indication+of+Interest+at+a+Reduced+Price+and+Premium/25698730.html Thu, 04 Dec 2025 08:00:00 -0500 A.33378433 NEUP O.01836073 O.67404898 http://www.streetinsider.com/Corporate+News/Neuphoria+counters+Lynx1+claims+in+proxy+fight+defense/25679556.html <p>Neuphoria Therapeutics Inc. (NASDAQ: NEUP) issued a detailed response defending against claims made by activist investor Lynx1 Master Fund LP in an ongoing proxy contest for board seats.</p><p>The biotechnology company disputes several assertions made by Lynx1, which owns a stake in Neuphoria and has nominated two directors to the board. Neuphoria urges shareholders to vote for its nominees Peter Miles Davies and David Wilson on the white proxy card while withholding votes from Lynx1's candidates.</p><p>According to Neuphoria's statement, Lynx1 contacted company representatives on November 8, delivered a director nomination notice on November 9, and submitted a non-binding acquisition proposal on http://www.streetinsider.com/Corporate+News/Neuphoria+counters+Lynx1+claims+in+proxy+fight+defense/25679556.html Mon, 01 Dec 2025 08:01:19 -0500 NEUP http://www.streetinsider.com/Press+Releases/Neuphoria+Provides+Facts%2C+Exposes+False+Narratives+in+Response+to+Lynx1+Fictions/25679539.html <p align="left">BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP (“Lynx1”) full of deception and distraction to deflect attention from its own limitations and its handpicked nominees’ shortcomings.</p> <p align="left"><strong>The Company urges stockholders to trust Neuphoria’s commitment to transparency and value creation over what it believes are Lynx1’s fabrications and misdirection http://www.streetinsider.com/Press+Releases/Neuphoria+Provides+Facts%2C+Exposes+False+Narratives+in+Response+to+Lynx1+Fictions/25679539.html Mon, 01 Dec 2025 08:00:00 -0500 A.33378433 NEUP O.01836073 O.67404898